Joshi Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 22.52%
- Profit Growth 27.95%
- Ebitda 341.84%
- Net Worth 167.15%
- Total Assets 56.90%
About Joshi Drugs
Joshi Drugs Private Limited (JDPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 September 2017 (Seven years and five months 5 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Narayan Joshi and Kishor Joshi serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2017PTC324016
- Company No.
324016
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Sep 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Joshi Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayan Joshi  | Director | 22-Sep-2017 | Current |
| Kishor Joshi | Director | 22-Sep-2017 | Current |
Financial Performance of Joshi Drugs.
Joshi Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.52% increase. The company also saw a substantial improvement in profitability, with a 27.95% increase in profit. The company's net worth Soared by an impressive increase of 167.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Joshi Drugs?
Unlock access to Joshi Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Kishona Pharmaceuticals Private LimitedNarayan Joshi and Kishor Joshi are mutual person
- Genford Drugs Private Limited
Narayan Joshi and Kishor Joshi are mutual person
- Sirois Pharmaceuticals Private Limited
Kishor Joshi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Joshi Drugs?
Unlock and access historical data on people associated with Joshi Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Joshi Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Joshi Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.